Clinical Trial Detail

NCT ID NCT03289039
Title Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

estrogen-receptor positive breast cancer

Therapies

Neratinib

Fulvestrant + Neratinib

Age Groups: adult senior

Additional content available in CKB BOOST